RBC Capital Initiates Coverage On Ligand Pharmaceuticals With Outperform Rating, Announces Price Target of $130
RBC Capital Initiates Coverage On Ligand Pharmaceuticals With Outperform Rating, Announces Price Target of $130
RBC資本開始覆蓋ligand pharmaceuticals，給予超越評級，並公佈130美元的目標價。
RBC Capital analyst Douglas Miehm initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and announces Price Target of $130.
RBC Capital分析師Douglas Miehm開始對Ligand Pharmaceuticals (納斯達克股票代碼: LGND)進行覆蓋，並給出超買評級，宣佈目標價爲130美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。